Marching against blood diseases: a report from the 51st Annual Meeting of the American Society of Hematology (December 5-8, 2009 - New Orleans, Lousiana, USA).
Lymphoma, leukemia, myeloma and many other malignant and nonmalignant blood diseases can have a severe impact on the sufferer's life expectancy, quality of life and functional abilities, and require treatment that in many cases is restricted to drug therapy. Many other issues were discussed during last year's American Society of Hematology annual meeting, but important information was also reported and discussed on possibilities for modifying the life cycle of blood cells as a pharmacological strategy aimed at addressing the abnormalities that result in hematological disease for improving the resulting signs and symptoms. New insight into such pharmacological approaches discussed during the meeting in New Orleans are summarized in the following report, which complements full detailed information contained in the original meeting abstracts available on the society's website.
Rabasseda
Xavier
X
Medical Department, Thomson Reuters, Provença 388, Barcelona, Spain. xavier.rabasseda@thomsonreuters.com
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001773:Blood Cells / Q000187:drug effects / Q000378:metabolism; D016503:Drug Delivery Systems; D006402:Hematologic Diseases / Q000188:drug therapy* / Q000503:physiopathology; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans
D000970:Antineoplastic Agents